Yefei Rong

Yefei Rong

Zhongshan, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Dynamic Profiling of Angiogenic, Metabolic, and Immune Checkpoint Biomarkers Predicts Chronic Critical Illness and Long-term Outcomes in Abdominal Sepsis.

Dynamic Profiling of Angiogenic, Metabolic, and Immune Checkpoint Biomarkers Predicts Chronic Critical Illness and Long-term Outcomes in Abdominal Sepsis.

Journal: Shock (Augusta, Ga.)

Published: March 26, 2026

The DIAPH3/RPL6 axis regulates the cGAS-STING pathway in pancreatic cancer.

The DIAPH3/RPL6 axis regulates the cGAS-STING pathway in pancreatic cancer.

Journal: European journal of medical research

Published: September 01, 2025

PPDPF-mediated regulation of BCAA metabolism enhances mTORC1 activity and drives cholangiocarcinoma progression.

PPDPF-mediated regulation of BCAA metabolism enhances mTORC1 activity and drives cholangiocarcinoma progression.

Journal: Oncogene

Published: September 13, 2024

Identification of Novel Tumor Pyroptosis-Related Antigens and Pyroptosis Subtypes for Developing mRNA Vaccines in Pancreatic Adenocarcinoma.

Identification of Novel Tumor Pyroptosis-Related Antigens and Pyroptosis Subtypes for Developing mRNA Vaccines in Pancreatic Adenocarcinoma.

Journal: Biomedicines

Published: January 28, 2024

Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial.

Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial.

Journal: Oncology letters

Published: September 25, 2023

Circulating cell-free DNA methylation-based multi-omics analysis allows early diagnosis of pancreatic ductal adenocarcinoma.

Circulating cell-free DNA methylation-based multi-omics analysis allows early diagnosis of pancreatic ductal adenocarcinoma.

Journal: Molecular oncology

Published: August 05, 2023

NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1.

NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1.

Journal: Digestive diseases and sciences

Published: April 23, 2022

Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdown in pancreatic cancer.

Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdown in pancreatic cancer.

Journal: Cell cycle (Georgetown, Tex.)

Published: December 07, 2021

PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.

PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.

Journal: Journal of Cancer

Published: April 11, 2021

Upregulated circRNA hsa_circ_0071036 promotes tumourigenesis of pancreatic cancer by sponging miR-489 and predicts unfavorable characteristics and prognosis.

Upregulated circRNA hsa_circ_0071036 promotes tumourigenesis of pancreatic cancer by sponging miR-489 and predicts unfavorable characteristics and prognosis.

Journal: Cell cycle (Georgetown, Tex.)

Published: January 28, 2021

Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors.

Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors.

Journal: Pancreas

Published: April 14, 2020

DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects.

DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects.

Journal: Journal of cellular and molecular medicine

Published: December 22, 2019

Showing 1-12 of 30

Last Updated: 09/26/2026